|
 China has four COVID-19 vaccines in the final stage of clinical
trials. At least three of those have already been offered to
essential workers under an emergency use programme launched in July.
Phase 3 clinical trials were proceeding smoothly and the vaccines
could be ready for the general public in November or December, CDC
chief biosafety expert Guizhen Wu said in an interview with state TV
late on Monday.
Wu, who said she has experienced no abnormal symptoms in recent
months after taking an experimental vaccine herself in April, did
not specify which vaccines she was referring to.
A unit of state pharmaceutical giant China National Pharmaceutical
Group (Sinopharm) and U.S.-listed Sinovac Biotech <SVA.O> are
developing the three vaccines under the state's emergency use
programme. A fourth COVID-19 vaccine being developed by CanSino
Biologics <6185.HK> was approved for use by the Chinese military in
June.
[to top of second column] |
Sinopharm said in July that its vaccine could be ready for public use by the end
of this year after the conclusion of Phase 3 trials.
Global vaccine makers are racing to develop an effective vaccine against the
virus which has killed more than 925,000 people. Leading Western vaccine makers
pledged earlier this month to uphold scientific study standards and reject any
political pressure to rush the process.
(This story corrects typo in lede; China's CDC uses American style center in
title)
(Reporting by Roxanne Liu and Tony Munroe in Beijing; Editing by Miyoung Kim and
Jane Wardell)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
